Acute Myeloid Leukemia Treatment Market Research Report - Forecast To 2027

Acute Myeloid Leukemia Treatment Market Information; by Disease Type (Myeloblastic, Promyeloctic, Myelomonocytic, Monocytic, Erythroleukemia, Megakaryocytic); by Treatment (Chemotherapy (Induction, Post Remission), Hematopoietic Stem Cell Transplantation) - Forecast to 2027

ID: MRFR/Pharma/2332-HCR | February 2021 | Region: Global | 80 pages

Market Synopsis of Acute Myeloid Leukemia Treatment Market


Market Scenario


Acute myeloid leukemia (AML) is a cancer of the myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid buildup of abnormal white blood cells causes interference in the production of normal blood cells. AML has a propensity to increase towards age. Replacement of normal bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells etc. which causes symptoms such as fatigue, breathlessness, easy bruising and bleeding, and increased risk of infection. The acute myeloid leukemia treatment market driving factors are rise in risk factors such as exposures to carcinogens such as ionizing radiation, chemicals etc. Presence of other blood disorders and genetics is also involved for the higher risk of AML. Other market drivers are increasing number of cancer hospitals, greater awareness, good reimbursement scenario etc. The acute myeloid leukemia treatment market constraints are poor cure rates of the present drugs, serious side effects of the drugs etc.


Considering all these factors the acute myeloid leukemia treatment market is expected to reach $ 1.2 billion by the end of 2023, acute myeloid leukemia treatment market is projected to growing at a CAGR of Approx 5.3 % during 2017-2023.

Figure 1 US Acute Myeloid Leukemia Treatment Market Share by Treatment, 2016 (%) Acute Myeloid Leukemia Treatment Market Share by Treatment, 2016


Key players of Acute Myeloid Leukemia Treatment Market


Key players profiled in the acute myeloid leukemia treatment market report are Johnson & Johnson, Pfizer Inc., Celgene Corporation, Ambit Biosciences Corporation, Cyclacel Pharmaceuticals Inc. Novartis AG and Sanofi, Bristol Myers Squibb and others.


Segments


The acute myeloid leukemia treatment market is segmented on the basis of disease type. Based on the disease type, the acute myeloid leukemia treatment market has been segmented as myeloblastic, promyeloctic, myelomonocytic, monocytic, erythroleukemia and megakaryocytic. Based on the treatment, the acute myeloid leukemia treatment market has been segmented as chemotherapy, and hematopoietic stem cell transplantation. Chemotherapy is further sub-segmented into induction and post remission.


Intended Audience



  • Global acute myeloid leukemia treatment solutions providers.

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Academic institutes and universities


 


Research Methodology


Research methodology Acute Myeloid Leukemia Treatment Market


Regional Analysis


US accounts for the maximum acute myeloid leukemia treatment market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and presence of large hospitals. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa acute myeloid leukemia treatment market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.


The report for Global Acute myeloid leukemia treatment Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current acute myeloid leukemia treatment market scenario which includes past and estimated future acute myeloid leukemia treatment market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 1.2 Billion
  • 2027: Significant Value
  •   CAGR   5.3% (2016-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Disease type, Treatment
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Johnson & Johnson, Pfizer Inc., Celgene Corporation, Ambit Biosciences Corporation, Cyclacel Pharmaceuticals Inc. Novartis AG and Sanofi, Bristol Myers Squibb and others
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Increasing number of cancer hospitals
  • Greater awareness
  • Good reimbursement scenario


  • Speak to Analyst Ask for Customization

    Table of Contents

    1 INTRODUCTION

    1.1 DEFINITION

    1.2 SCOPE OF STUDY

    1.2.1 RESEARCH OBJECTIVE

    1.2.2 ASSUMPTIONS & LIMITATIONS

    1.2.2.1 ASSUMPTIONS

    1.2.2.2 LIMITATIONS

    1.3 MARKET STRUCTURE:

    2 RESEARCH METHODOLOGY

    2.1 RESEARCH PROCESS:

    2.2 PRIMARY RESEARCH

    2.3 SECONDARY RESEARCH:

    3 MARKET DYNAMICS

    3.1 DRIVERS

    3.2 RESTRAINTS

    3.3 OPPORTUNITIES

    3.4 MACROECONOMIC INDICATORS

    4 MARKET FACTOR ANALYSIS

    4.1 PORTERS FIVE FORCES MODEL

    4.2 BARGAINING POWER OF SUPPLIERS

    4.3 BARGAINING POWER OF BUYERS

    4.4 THREAT OF NEW ENTRANTS

    4.5 THREAT OF SUBSTITUTES

    4.6 INTENSITY OF RIVALRY

    5 GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY DISEASE TYPE

    5.1 MYELOBLASTIC

    5.2 PROMYELOCTIC

    5.3 MYELOMONOCYTIC

    5.4 MONOCYTIC

    5.5 ERYTHROLEUKEMIA

    5.6 MEGAKARYOCYTIC

    6 GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY BY TREATMENT

    6.1 CHEMOTHERAPY

    6.1.1 INDUCTION

    6.1.2 POST REMISSION

    6.2 HEMATOPOIETIC STEM CELL TRANSPLANTATION

    7. GLOBAL ACUTE MYELOID LEUKEMIA TREATMENT MARKET, BY REGION

    7.1 NORTH AMERICA

    7.1.1 INTRODUCTION

    7.2 EUROPE

    7.2.1 INTRODUCTION

    7.3 ASIA-PACIFIC

    7.3.1 INTRODUCTION

    7.4 MIDDLE EAST & AFRICA

    7.4.1 INTRODUCTION

    8. COMPETITIVE LANDSCAPE

    8.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

    8.1.1 STRATEGIC PARTNERSHIP

    8.1.2 MERGER & ACQUISITION

    9 COMPANY PROFILE

    9.1 JOHNSON & JOHNSON

    9.1.1 OVERVIEW

    9.1.2 PRODUCT OVERVIEW

    9.1.3 FINANCIALS

    9.1.4 KEY DEVELOPMENTS

    9.2 PFIZER INC.

    9.2.1 OVERVIEW

    9.2.2 PRODUCT OVERVIEW

    9.2.3 FINANCIALS

    9.2.4 KEY DEVELOPMENTS

    9.3 CELGENE CORPORATION

    9.3.1 OVERVIEW

    9.3.2 PRODUCT OVERVIEW

    9.3.3 FINANCIALS

    9.3.4 KEY DEVELOPMENT

    9.4 AMBIT BIOSCIENCES CORPORATION

    9.4.1 OVERVIEW

    9.4.2 PRODUCT OVERVIEW

    9.4.3 FINANCIALS

    9.4.4 KEY DEVELOPMENTS

    9.5 CYCLACEL PHARMACEUTICALS INC.

    9.5.1 OVERVIEW

    9.5.2 PRODUCT OVERVIEW

    9.5.3 FINANCIALS

    9.5.4 KEY DEVELOPMENTS

    9.6 NOVARTIS AG

    9.6.1 OVERVIEW

    9.6.2 PRODUCT OVERVIEW

    9.6.3 FINANCIALS

    9.6.4 KEY DEVELOPMENTS

    9.7 SANOFI

    9.7.1 OVERVIEW

    9.7.2 PRODUCT OVERVIEW

    9.7.3 FINANCIALS

    9.7.4 KEY DEVELOPMENTS

    9.8 BRISTOL MYERS SQUIBB

    9.8.1 OVERVIEW

    9.8.2 PRODUCT OVERVIEW

    9.8.3 FINANCIALS

    9.8.4 KEY DEVELOPMENTS

    9.9 OTHERS

    10 CONCLUSION

    10.1 KEY FINDINGS

    10.1.1 FROM CEO’S VIEWPOINT

    10.1.2 UNMET NEEDS OF THE MARKET

    10.2 KEY COMPANIES TO WATCH

    10.3 PREDICTION OF ACUTE MYELOID LEUKEMIA TREATMENT INDUSTRY

    11 APPENDIX